Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of “Buy” from Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been given an average recommendation of “Buy” by the six ratings firms that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $41.1667.

KNSA has been the topic of a number of recent research reports. Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, July 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $33.21 on Thursday. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 830.46 and a beta of 0.14. Kiniksa Pharmaceuticals International has a one year low of $17.82 and a one year high of $34.55. The business has a 50-day simple moving average of $29.55 and a 200 day simple moving average of $25.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 17,000 shares of the firm’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.35, for a total transaction of $549,950.00. Following the transaction, the chief accounting officer directly owned 33,041 shares of the company’s stock, valued at approximately $1,068,876.35. This trade represents a 33.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 16,200 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $33.77, for a total transaction of $547,074.00. Following the completion of the sale, the chief operating officer directly owned 40,215 shares of the company’s stock, valued at $1,358,060.55. This represents a 28.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 679,686 shares of company stock valued at $21,274,787 over the last quarter. Company insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Rubric Capital Management LP raised its position in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Braidwell LP raised its holdings in Kiniksa Pharmaceuticals International by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock worth $68,289,000 after acquiring an additional 557,934 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after acquiring an additional 233,668 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.